ImmuCell Corporation (NASDAQ:ICCC – Get Free Report)’s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $8.81 and traded as high as $10.00. ImmuCell shares last traded at $9.79, with a volume of 20,133 shares trading hands.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on ICCC shares. Weiss Ratings upgraded ImmuCell from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Tuesday, August 18th. Wall Street Zen raised ImmuCell to a “strong-buy” rating in a research report on Saturday, June 27th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, ImmuCell currently has an average rating of “Hold”.
View Our Latest Stock Analysis on ICCC
ImmuCell Stock Up 0.7%
ImmuCell (NASDAQ:ICCC – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The biotechnology company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.15. The company had revenue of $7.19 million during the quarter, compared to analyst estimates of $5.40 million. ImmuCell had a net margin of 2.57% and a return on equity of 2.69%.
Insider Buying and Selling at ImmuCell
In related news, CEO Boekhorst Paul Francis Oliv Te purchased 8,000 shares of the firm’s stock in a transaction dated Thursday, June 18th. The stock was bought at an average price of $9.49 per share, for a total transaction of $75,920.00. Following the purchase, the chief executive officer directly owned 17,785 shares in the company, valued at approximately $168,779.65. This trade represents a 81.76% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.70% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On ImmuCell
Institutional investors have recently bought and sold shares of the company. Militia Capital Management LLC purchased a new stake in ImmuCell in the first quarter worth $114,000. Mesirow Financial Investment Management Inc. raised its stake in shares of ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after buying an additional 24,303 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of ImmuCell by 3.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 1,749 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after buying an additional 2,907 shares during the last quarter. Hedge funds and other institutional investors own 13.47% of the company’s stock.
ImmuCell Company Profile
ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.
The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.
Featured Articles
- Five stocks we like better than ImmuCell
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.
